TAKHZYRO now available in Newfoundland & Labrador


We love sharing amazing news, and now we have even more to love! On March 17th, 2021, lanadelumab (TAKHZYRO), a subcutaneous monoclonal antibody inhibitor of plasma kallikrein, was added to the Newfoundland & Labrador Prescription

TAKHZYRO now available in Newfoundland & Labrador2021-05-03T15:14:46-06:00

April 6 is the day for HAEGARDA in Canada!


We are thrilled to let you know that starting April 6, HAEGARDA, a subcutaneous C1 Esterase Inhibitor (human), manufactured by CSL Behring, will be included on the Canadian Blood Services (CBS) formulary. This means that all

April 6 is the day for HAEGARDA in Canada!2021-05-03T09:34:50-06:00

Takhzyro Added to the NIHB Formulary


We are happy to share that eligible HAE patients across Canada who have coverage under the Non-Insured Health Benefits (NIHB) for First Nations and Inuit Program can now access lanadelumab (TAKHZYRO) as a limited use

Takhzyro Added to the NIHB Formulary2021-03-11T12:53:09-06:00

Takhzyro soon available in Manitoba


Great news for eligible HAE patients in Manitoba! Starting April 1, 2021, Manitoba Pharmacare will list lanadelumab (Takhzyro) as part of Exception Drug Status. To find out more, please make an appointment with your HAE

Takhzyro soon available in Manitoba2021-03-11T10:06:30-06:00

Takhzyro is now available in BC


Have you heard the latest fantastic news? British Columbia has recently started providing access to lanadelumab (TAKHZYRO) to eligible HAE patients. For further details and to learn how to access lanadelumab through the province's Expensive

Takhzyro is now available in BC2021-03-04T11:51:28-06:00
Go to Top